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Medicare MTM eligibility criteria. The Medicare MTM eligibility criteria need to be 
modified in order to eliminate their disparity implications.
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Objectives: To examine racial and ethnic disparities in health status, health ser-
vices utilizations and costs, and medication utilization based on Medicare medi-
cation therapy management (MTM) eligibility status. Greater disparities among 
MTM-ineligible than MTM-eligible individuals would suggest that MTM eligibility 
criteria have the potential to exacerbate racial and ethnic disparities in health out-
comes. MethOds: This is a retrospective cross-sectional analysis of the Medicare 
Current Beneficiary Survey (2007-2008). A difference-in-differences model was used 
by including in regression models interaction terms between dummy variables for, 
e.g., non-Hispanic Blacks and MTM eligibility criteria, when examining racial dis-
parities. Both main and sensitivity analyses were conducted to represent the ranges 
of the MTM eligibility thresholds used by insurance plans in 2010. The interaction 
term was interpreted on both the multiplicative term and the additive term. Various 
regression models were used. Results: Whites were more likely to report self-
perceived good health status than Blacks and Hispanics among both MTM-eligible 
and MTM-ineligible populations. Disparities were greater among MTM-ineligible 
than MTM-eligible populations (e.g., on additive term, difference in odds= 1.94 and 
P< 0.01 for Whites and Blacks; difference in odds= 2.86 and P< 0.01 for Whites and 
Hispanics in main analysis). When examining racial disparities, activities of daily 
living, instrumental activities of daily living, and generic possession ratio produced 
similar findings. Whites had a higher number of physician visits than Hispanics 
and the disparities were greater among the MTM-ineligible than MTM-eligible 
individuals (incidence rate ratio= 1.40; P< 0.01). Analyses on chronic conditions, 
costs of physician visits, hospitalizations, and total health care costs produced 
similar patterns on ethnic disparities. No other variables exhibited significant find-
ings. cOnclusiOns: Current MTM eligibility criteria may potentially aggravate 
existing racial and ethnic disparities in health services utilization and costs and 
medication utilization measures. Future research should examine strategies to 
remediate the effects of MTM eligibility criteria on racial and ethnic disparities.
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Objectives: To understanding the clinical care pathway and patient character-
istics of those patient visits that use the catheterization laboratory (cath lab) but 
do not result in a percutaneous coronary intervention (PCI) and/or coronary artery 
bypass surgery (CABG) procedure shortly thereafter. The target population is those 
patient visits that are outpatient and elective, rather than those coming in through 
the emergency room, or inpatient admissions. MethOds: The Premier hospital 
database from July 1, 2011 through June 30, 2012 was utilized as the data source. 
This database contains complete patient billing, hospital cost, and coding histo-
ries from more than 600 hospitals and ambulatory facilities throughout the United 
States. Eligible patients were > age 45 at the time of the coronary angiography 
visit, and must have had one of the following primary diagnosis of Atherosclerosis 
or chest pain using the International Classification, 9th Revision (ICD-9): 414.01, 
786.5, or 786.59. Patient visits with a diagnosis code(s) for myocardial infarction or 
stroke/trans-ischemic attack were excluded. Patients that died during the visit were 
excluded as well. Results: Of 354,790 coronary angiography visits identified, 68,026 
visits (19.2%) met the inclusion criteria. Only 7% of patient visits (4,788) resulted in 
a return visit within 60 days for a PCI (29%), CABG (71%), or both (< 1%). Less than 2% 
(81) came back to the hospital through the ER. Total median coronary angiography 
cost per visit for the group of interest was $2,565, with the cardiology department 
accounting for 57% ($1,470) of costs. Left heart cardiac catheterization was the most 
common procedure (86%). cOnclusiOns: There appears to be a substantial popu-
lation receiving elective coronary angiography, with no immediate action resulting 
from that visit. Technologies that could enable another clinical pathway to avoid the 
cath lab and an invasive procedure may lead to lower hospital costs.
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Objectives: Inpatient admissions may represent an important opportunity for the 
review and revision of treatment regimens of type 2 diabetes mellitus (T2DM) patients. 
This retrospective study seeks to assess the impact of inpatient admissions on modi-
fication of T2DM pharmacotherapy regimens. MethOds: A retrospective cohort of 
Humana Medicare Advantage Prescription Drug (MAPD) and commercial patients 
with T2DM with at least one inpatient stay between January 2007 and December 2012 
was identified (IPH group). The date of first inpatient hospitalization was defined 
as the index date. Patients with at least 12 months of continuous eligibility pre-
index and post-index were identified. A non-inpatient admission comparison group 
(non-IPH group) of T2DM patients was propensity score-matched on age, gender, 
plan enrollment and diabetes complication score. The primary outcome of interest 
was treatment modification, defined as an addition, switch or discontinuation of an 
anti-diabetic drug class within 10 days post-discharge. Results: The study cohort 
comprised 34,624 patients with T2DM (17,312 matched pairs). The IPH group had 
Objectives: Ontario (ON) and Québec (QC), the two largest provinces in Canada, 
have public programmes for immunization against influenza. We aimed at reviewing 
and presenting differences and similarities between the two provinces, and identi-
fying resources allocated to respective programmes. MethOds: Government and 
health professions information sites (medicine, nursing, pharmacy) were searched, 
as well as the grey literature, supplemented by direct communication with health 
care professionals. Resources (professional services and materials) were identified 
and listed, considering both Ministry of Health and patient perspectives. Results: 
Major differences were identified in both eligibility of patients and provision of flu 
shots (FS). QC limits the FS to the elderly (60 years or older), infants (6-23 months) 
and persons “at risk” (persons with chronic conditions, living in isolated communi-
ties, health care workers, caregivers and those travelling to endemic areas). ON has a 
universal programme covering the entire population except infants (under 6 months 
of age) and persons in whom the vaccine is contraindicated. In QC, FS are admin-
istered mainly by public health nurses and physicians, while in ON, FS can also be 
injected by trained and certified pharmacists (for persons 5 years of age and older). 
ON Pharmacies where FS are administered can directly bill the Ministry of Health 
for an honorarium for each injection. There are also differences between rural and 
urban areas with regard to eligibility in the case of QC and possibly access to FS in 
both provinces. cOnclusiOns: The ON programme is more comprehensive than 
the QC programme, both by expanded population eligibility and through increased 
availability of resources by making FS available at certified pharmacies. This work 
will prepare the ground for a future comparative economic analysis.
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Objectives: To describe trends in eligibility thresholds of Medicare medication 
therapy management (MTM) services to identify patterns that may hinder eligi-
bility/enrollment. MTM Services were established in 2006 as part of the Medicare 
outpatient prescription drug (Part D) benefit. MTM eligibility was based on number 
of chronic conditions, Part D medications, and total drug costs. To increase MTM 
enrollment rate, the Centers for Medicare and Medicaid Services (CMS) lowered the 
allowable eligibility thresholds to at or below 3 for number of chronic diseases and 
at or below 8 for Part D drugs, and drug cost threshold from $4,000 to $3,000 in 2010. 
However, an increase in MTM enrollment rates has not been seen. MethOds: This 
study analyzed data extracted from the Medicare Part D MTM Programs Fact Sheets 
published on the cms.gov website. Fact Sheets for 2008-2013 were used to search 
for changes and trends over time that may potentially affect the enrollment rate 
for Medicare beneficiaries. These years were the only ones available from the cms.
gov website. Results: In 2008, 48.7% plans opened MTM enrollment to patients 
with only two chronic disease states, while the other half restricted enrollment 
to patients with a minimum number of three to five chronic disease states. Data 
for years 2011-2013 indicate that approximately 20% of plans opened enrollment 
to patients with 2 chronic disease states, with the remaining 80% restricting 
enrollment to patients with 3 or more chronic diseases. The trends for both 
Medicare Advantage plans and independent Part D plans were similar. CMS pol-
icy change in 2010 is also correlated with increase proportion of plans set their 
eligibility threshold at 8 part D drugs, the maximum number allowa-
ble. cOnclusiOns: Changes to the eligibility thresholds may have been barriers 
for increased MTM enrollment. CMS needs to find alternative strategies to increase 
MTM enrollment.
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Objectives: To determine whether the implementation of the Medicare Part D in 
2006 was associated with changes in differential racial and ethnic disparity pat-
terns between the individuals ineligible for medication therapy management (MTM) 
services and MTM-eligible individuals. If Part D implementation is not associated 
with reductions in greater racial and ethnic disparities in MTM-ineligible than the 
MTM-eligible individuals, the urgency for modifying MTM eligibility criteria would 
be even increased. MethOds: Data from the Medicare Current Beneficiary Survey 
were analyzed. A generalized difference-in-differences analyses, difference-in-dif-
ferences-in-differences-in-differences (DDDD) model, was used to examine changes 
in difference in disparities between the MTM-ineligible and MTM-eligible individu-
als from 2004-2005 to 2007-2008 in relation to the changes from 2001-2002 to 2004-
2005. Disparities were examined in health outcomes, health services utilizations/
costs, and medication utilization patterns. MTM eligibility criteria for 2010 were 
examined and both main and sensitivity analyses were conducted to represent the 
ranges of the MTM eligibility thresholds used by insurance plans. Various regression 
models varied according to the type of dependent variables. Results: The main 
analysis found no significant DDDD values. For racial disparities, according to some 
sensitivity analyses, Part D implementation was associated with a reduction in 
greater racial disparities among the MTM-ineligible and MTM-eligible individuals 
in activities of daily living (DDDD= 1.13; P= 0.03 for one analysis) and instrumental 
activities of daily living (DDDD= 0.95; P= 0.03 for one analysis). For ethnic disparities, 
Part D implementation was associated with reduction in any greater disparities 
among the MTM-ineligible than MTM-eligible individuals in costs of physician vis-
its (DDDD= -4613.71; P= 0.04 for one analysis) and high risk medication utilization 
(DDDD= -0.10; P= 0.03 for one analysis). cOnclusiOns: Part D implementation is 
not consistently associated with reductions in the disparity implications of the 
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Objectives: Studies have shown that the use of psychotropic medications such as 
sedative hypnotics have a significant association with risk of falls in older adults. 
However, very few studies have assessed the association with poor sleep, medications 
used to improve sleep, and the combined effect of these variables on the risk of falls. 
The objectives were: 1) to determine the prevalence of sleep problems, use of sleep 
medications and falls and 2) to evaluate the association between sleep problems, sleep 
medications, and falls in adults aged 65 or older. MethOds: The study population 
comprised a nationally representative sample of non-institutionalized adults aged 
65 years or older participating in the 2010 Health and Retirement Study. Prevalence 
of sleep problems, sleep medication use and falls was calculated. Logistic regression 
modeling was used to examine the effect of sleep problems, sleep medications, and 
both on the risk of falls after controlling for covariates. Statistical analysis was per-
formed using SAS 9.4 statistical software. Results: In 9,937 community-dwelling 
older adults, 36% had fallen in the past two years. 71% reported sleep problems and 
21% reported taking medications or other treatments to help sleep. Older adults who 
do not have sleep problems and take sleep medications (OR= 1.50, 95%CI= 1.10-2.03) 
and those who do have sleep problems and take sleep medications (OR= 1.28, 95%CI= 
1.07-1.54) have a significant risk of falls, compared to older adults who do not have 
sleep problems and do not take sleep medications. cOnclusiOns: Sleep problems, 
use of sleep medications, and occurrence of falls are common among older adults. 
Consistent with previous literature, sleep medication use predicted falls. However, 
those with sleep problems not taking sleep medication did not have significant risk 
of falls as has been previously reported. Health care professionals should consider 
medication-associated risk when treating sleep problems in older adults.
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Objectives: This 2-year long prospective observational study was undertaken 
to characterize the most common medications involved in causing Adverse Drug 
Reactions (ADRs) in the Indian elderly inpatients. MethOds: The records of 1510 
inpatients aged 60 years or above, either sex, were assessed using subjective and 
objective parameters to identify ADRs. Results: Of the total 1510 patient records 
evaluated, 228 ADRs were noted in 197 patients. The prevalence of ADRs in Indian 
elderly inpatients was found to be 13%. Type A ADRs accounted for 85% of the total 
ADRs. The most frequently occurring ADR was hypotension. The 3 most frequently 
involved drug classes in ADRs were Cardiovascular (CVS) drugs (70%), followed by 
Blood and blood forming organs (12%) and Anti-infectives (6.5%). Within the CVS 
drugs, antihypertensives, diuretics and lipid modifying drugs were the causative 
agents. cOnclusiOns: Cardiovascular agents were the most commonly involved 
drugs associated with ADRs in the elderly inpatients. In view of the fact that these 
drugs are well established in clinical practice, prevention of the CV illnesses seems 
to be the only route to minimize the adverse drug reactions for the Indian popula-
tion.
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Objectives: The relationship between medically assisted reproduction (MAR) use 
and the risk of major congenital malformations (MCM) is controversial. Multiplicity 
is a recognized adverse effect of MAR; nevertheless, there is no consensus on the 
incremental risk. Our meta-analysis summarizes the literature on fertility treat-
ments and risks for the newborn, explains discrepancies between studies, and 
identifies the gaps in knowledge for future research. MethOds: We carried out a 
systematic review to identify published papers between 1966 and 2012 in Medline, 
Embase and Cochrane Central Register of Controlled Trials. We included observa-
tional studies and randomized clinical trials related to the risk of multiplicity or 
MCM conceived following ovarian stimulation (OS) alone, intrauterine insemination 
(IUI) and in-vitro fertilization (IVF) with related procedures compared to sponta-
neously conceived infants or infants conceived using other MAR. Results: We 
identified 238 eligible studies. Among them, 186 reported data on IVF, 37 reported 
data on OS used alone and 21 on IUI use. Compared to natural conception, OS used 
alone was associated with a greatly increased risk of multiplicity (RR 11.07, 95% CI 
6.94-17.67), major congenital anomalies of nervous system (RR 1.88, 95% CI 1.20 
-2.96) and major musculoskeletal malformations (RR 1.38, 95% CI 1.06-1.79). The 
risk of multiplicity further decrease and the risk of major musculoskeletal mal-
formations increase when data were restricted to clomiphene citrate (the first line 
OS). Compared to natural conception, the use of IUI was associated with greatly 
increased risk of multiplicity (RR 10.16, 95% CI 7.35-14.06) and major musculoskel-
etal malformations (RR 1.66, 95% CI 1.26-2.18). cOnclusiOns: A limited number 
of observational studies focused on the risk of multiplicity and MCM following OS 
alone and IUI compared the data on IVF use. Results suggest that overall OS used 
with or without IUI increases the risk of multiple birth and some types of MCM.
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statistically significantly higher rates of therapy addition compared to the non-IPH 
group (2.1% vs. 0.9%; p< 0.0001), switches in therapy (2.3% vs. 0.6%; p< 0.0001) and 
treatment discontinuations (3.9% and 3.2%; p= 0.001). There were multiple statistically 
significant differences between the IPH and non-IPH groups across several antidia-
betic drug classes regarding therapy addition, switch or discontinuation. For example, 
IPH patients were 12.5 times more likely to add basal insulin compared to non-IPH 
patients (95% CI, 3.7 - 42.4; p< 0.0001). cOnclusiOns: Inpatient admission of patients 
with T2DM was associated with more frequent treatment modifications to their pre-
admission treatment regimen compared to a matched cohort of patients without 
inpatient admissions. An inpatient admission represents an opportunity to modify 
pre-admission diabetic treatment regimens. Future studies are needed to determine 
if such modifications are associated with improvements in patient outcomes.
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Objectives: Community-acquired pneumonia (CAP) represents a considerable 
burden in senior adults in Russia. In adults > 18 years, the incidence is ~280 per 
100K, with > 1% of treated cases resulting in death. The risk of CAP increases with 
increasing age and comorbidities. We assessed resource use and outcomes of CAP in 
Russia to characterize disease burden in Russian adults. MethOds: We conducted a 
retrospective chart review in a central Russian region of Tver for samples of 500 and 
400 patients treated in inpatient and outpatient settings respectively. All patients 
were 50 years of age and older and were not transferred from a hospital or previ-
ously hospitalized in the past 2 weeks. Data were collected regarding age, gender, 
comorbidities, referral patterns, outcomes, resource use, employment status, and 
productivity loss. Results: Among inpatient CAP episodes the mean age was 65.9 
years and 55.4% were male. Most of the hospital admissions were referred by outpa-
tient physician (63.4%), 25.4% were admitted by ambulance and 11.2% self-referred. 
Among outpatient cases the mean age was 65.5 years and 52% were male. Based on 
comorbidities, 75.0% of inpatient and 68.8% of outpatient cases were at moderate/
high risk of pneumonia. The overall length of stay among inpatient cases was 13.6 
days. Mean length of stay was similar across age groups and by risk categories. 
Outpatient cases received an average of 5 procedures, including one X-ray per case, 
and an average 8.4 days of antibiotic therapy. Employed patients below retirement 
age comprise 12.8% and 18.3% of the inpatient and outpatient cases, respectively, 
and days lost from work per patient of working age was 8.0 (inpatient) and 7.0 
(outpatient). cOnclusiOns: CAP is a significant cause of health care utilization in 
adults in Russia. Most CAP patients have chronic comorbidities. Resource utilization 
was similar across age and risk groups.
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Objectives: To analyze the feasibility of a collaborative evidence-based consensus-
driven pathway in rheumatoid arthritis (RA). Unsustainable cost trends in health 
care have been the focus of much debate. RA has been a particular target of these 
concerns due to its chronic nature, arsenal of expensive therapeutics, variability in 
patterns of care, care coordination issues and often absent objective determinants 
of disease activity and treatment responsiveness. Pathway programs have been sug-
gested as a means to decrease treatment variability thereby improving quality and 
cost. MethOds: CareFirst BlueCross BlueShield and Cardinal Health collaborated 
with rheumatologists in the CareFirst network to develop a payer-sponsored RA 
pathway program. Participation was voluntary but reimbursement enhancements 
were offered to mitigate cost of provider adoption and compliance. Results: 80 
physicians from 37 CareFirst community network practices signed participation 
agreements. A steering committee of 12 physicians created the pathway with the 
following unique elements: obligatory use of a real-time decision-support and 
data-capture tool; requirement for a clinical disease activity index (CDAI) at each 
physician visit; use of disease-modifying antirheumatic drugs as first-line treat-
ment for at least 12 weeks before use of biologic agents; and a requirement that 
dose, schedule, and adjustments for biologic agents follow package label prescribing 
guidelines. A total of 1800 unique RA patients entered the program. CDAI capture 
through the decision support tool exceeded 70% of visits. DMARD rule compliance 
resulted in an 8% reduction in overall biologic agent use. Claims-validated com-
pliance with initial infused biologic agent dose and schedule by label increased 
from 40% to 53%. Pathway adherence was without a consequent increase in CDAI 
scores. cOnclusiOns: High-level pathway program adoption suggests feasibility of 
this approach. Label-based prescribing of DMARD and biologic agents was not asso-
ciated with higher CDAI scores, confirming that evidenced-based algorithms do not 
jeopardize patient outcomes. Opportunity exists to improve biologic use compliance.
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